We're relentlessly pursuing solutions and disrupting treatment paradigms where needed most.
Avadel is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. We are disrupting treatment paradigms where it's needed most — starting with narcolepsy.Learn more about our focus
Our Leadership Team
We are led by a diverse team of experts in their respective fields, each of whom helps to ensure the success of our business and, ultimately, the well-being of patients.
Gregory J. Divis serves as our Chief Executive Officer and a member of our Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles within the company, including Chief Operating Officer, Executive Vice President, and Chief Commercial Officer. Greg brings over 30 years of experience in building and leading business and financial operations within the pharmaceutical industry. Prior to joining Avadel, Greg served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. He also served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women's health. Prior to Lumara, Greg held general management, sales, marketing, and business development roles at Schering-Plough, which was acquired by Merck & Co., Inc., and Sanofi-Aventis. Greg earned his bachelor's degree from the University of Iowa.
Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs, in December 2020. Prior to joining Avadel, Jennifer was Vice President, Medical Affairs, at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Prior to her time at AMAG Pharmaceuticals, she was Director of Medical Affairs at Lumara Health, a specialty branded pharmaceutical company focused on women's health, and previously served at Mallinckrodt Pharmaceuticals. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Jennifer has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development in high-risk pregnancies. She graduated summa cum laude with a bachelor's degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy.
Richard Kim was appointed Chief Commercial Officer in February 2021. Prior to joining Avadel, he served as the President of US Commercial & Strategic Marketing at Intercept Pharmaceuticals, Inc. During his time there, he helped to successfully launch OCALIVA™ (obeticholic acid), the first new treatment in nearly 20 years for the orphan disease primary biliary cholangitis, and led the launch strategy for NASH. Before Intercept, Richard served as General Manager, Hepatitis C Worldwide Commercialization, at Bristol-Myers Squibb, where he led the successful worldwide launch of DAKLINZA™ (daclatasvir). Prior to this, he held several roles of increasing responsibility leading sales, operational, and strategic marketing teams at Bristol-Myers Squibb, including Vice President, SPRYCEL™ Brand Lead, Oncology Global Marketing; Vice President, US In-Line Oncology and Global Marketing; and Vice President, East Area Sales, Cardiovascular and Metabolics. Prior to his time at Bristol-Myers Squibb, Richard held a range of senior positions in the US, Canada, and Australia at Schering-Plough, which was acquired by Merck & Co., Inc. Richard received a bachelor's degree in chemistry from the University of Alberta.
Scott Macke joined Avadel in November 2010 and has more than 25 years of pharmaceutical industry experience with a strong focus on both supply chain and project management. Prior to Avadel, Scott held roles of increasing responsibility at KV Pharmaceuticals, including Senior Director, Project Management, where he led the company's PMO, and at Mallinckrodt Pharmaceuticals where he began his career as a peptide chemist before moving into roles that included marketing (new products, active pharmaceutical ingredients) and drug product project management. Scott received his BS (biology) from Southwest Missouri State and a Master of Business Administration from Maryville University.
Thomas McHugh was appointed Chief Financial Officer in December 2019. Prior to joining Avadel, Tom served as Senior Vice President of Finance of Ironshore Pharmaceuticals Inc., where he built and led the US finance, accounting, and treasury functions and supported Ironshore's new product launch. Before his time at lronshore, Tom was the Chief Financial Officer and Treasurer at Lumara Health, a specialty branded pharmaceutical company focused on women's health. While at Lumara he supported a number of key strategic initiatives, including a new product launch, a restructuring, and a sale of the company. Prior to joining Lumara, Tom was a Managing Director and Global Controller at BearingPoint, a global consultancy, and prior to that, served as Chief Financial Officer at Huttig Building Products, Inc. Tom began his career in public accounting at PricewaterhouseCoopers. He earned his bachelor's degree in finance from Bentley University and a master's degree in accounting from Northeastern University.
Jerad G. Seurer is the General Counsel and Corporate Secretary, as well as the Compliance Officer, for Avadel Pharmaceuticals. Jerad joined Avadel in 2017 after approximately 13 years at Mallinckrodt Pharmaceuticals, where he held numerous positions, including Group General Counsel for the Generics/API business, as well as Vice President of Integration Management. Prior to Mallinckrodt, Jerad was in private legal practice at Wyatt Tarrant & Combs, Marsh Fischmann & Breyfogle, and Wilhelm Law Service. Jerad is currently licensed in Missouri, Minnesota, South Dakota, Wisconsin (inactive), and the United States Patent & Trademark Office. He received a BS in biology, Master of Arts in biology, and Juris Doctorate in law from the University of South Dakota.
Rosemarie Tully is a registered pharmacist with more than 20 years of pharma, drug delivery, biotech and medical device industry experience. Most recently, Rosemarie was Chief Operating Officer at Neuromod Devices Limited, a breakthrough neuromodulation company focused on the unmet needs of patients with chronic neurological conditions, including tinnitus. Previously, Rosemarie held senior roles in corporate development and strategy at Sigmoid Pharma Limited, Elan Corporation plc (now Perrigo Company plc), and was a management consultant at McKinsey & Company. Rosemarie has extensive operational leadership, fundraising, corporate business development and licensing experience. Rosemarie completed her BSc (Hons) Pharmacy degree at Trinity College Dublin, Ireland, and her master's degree in business administration at INSEAD, France.
Prior to joining Avadel in December 2019, Dr. Jason Vaughn was Principal at Wyatt Pharma Consulting, LLC, where he led several development programs for client companies, including Avadel. Before Wyatt Pharma, he was Senior Director and Vice President, Process Technology Development, for the North American region of Patheon Pharmaceuticals, a ThermoFisher Scientific company, where he was responsible for assisting client companies in product development, scale-up, and commercialization. Jason also served as Vice President, Pharmaceutical Development, for Banner Life Sciences, a specialty pharmaceutical company focused on developing products using the 505(b)2 pathway. There, he led a technical team developing a number of oral, modified-release products for IND-enabled clinical studies, registration, scale-up, NDA regulatory submission, and commercialization readiness for products, including Bafiertam™. Prior to Banner, Jason served as Director, Formulation Development, for Patheon Pharmaceuticals, leading teams focused on development, scale-up, registration, and commercialization of oral modified-release dosage. He received a BS in pharmacy and a PhD in pharmaceutics from the University of Texas at Austin.
Angie Woods was appointed Vice President, People and Culture, in May 2021. Angie has more than 25 years of experience in human resources, holding positions of increasing responsibility spanning multiple industries, global organizations, and diverse workforces. Prior to joining Avadel, Angie served as Vice President, Human Resources, at Mallinckrodt Pharmaceuticals, where she held various leadership roles over seven years with oversight for developing and leading people and talent strategies in support of the company's launch of new products, multiple M&A integrations, culture building, and business transformation. Prior to Mallinckrodt, Angie was Vice President, Human Resources, at Furniture Brands International, during which time she led a team of HR professionals to align and implement people and talent strategies in support of the transformation of the global manufacturing and supply chain organization, as well as the Designer Brands business from product design through delivery to the customer. Angie received a bachelor's degree in finance from Southern Illinois University, Carbondale.
Board of Directors
Geoffrey M. Glass has been a member of the Avadel Board of Directors since July 2018 and became Chairman of the Board in December 2018. Geoff is the founder and Chief Executive Officer of Kiniciti, a company focused on accelerating the advancement of the cell and gene therapy sector. Geoff has spent over 25 years helping lead services and therapeutic companies in the life sciences sector, including as an Operating Partner at LongueVue Capital, Chief Executive Officer of Sancilio Pharmaceuticals, and as a President at Patheon. Before Patheon, Geoff served on Valeant Pharmaceutical’s (now Bausch Health’s) executive team for nearly five years, first as Chief Information Officer and then running the company’s Asia business. Geoff received a BA in economics and political science from the University of Arizona.
Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of our Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles within the company, including Chief Operating Officer, Executive Vice President, and Chief Commercial Officer. Greg brings over 25 years of experience in building and leading business and financial operations within the pharmaceutical industry. Prior to joining Avadel, Greg served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. He also served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women's health. Prior to Lumara, Greg held general management, sales, marketing, and business development roles at Schering-Plough, which was acquired by Merck & Co., Inc., and Sanofi-Aventis. Greg earned his bachelor's degree from the University of Iowa.
Peter J. Thornton has been a member of the Avadel Board of Directors since June 2017. He is the President and Chief Financial Officer of Envetec Sustainable Technologies Limited, an Irish company that provides technologies to safely treat biohazardous laboratory waste at source while reducing carbon emissions. Peter is also Director of Oculer Limited – an Irish company focused on developing and commercializing proprietary rapid microbiology assays and instruments. Previously, Peter held leadership roles as Chief Financial Officer of Technopath Clinical Diagnostics, an Irish company that provides quality control solutions to clinical laboratories, Senior Vice President - Business Integration for Alkermes plc, and Senior Vice President - Corporate and Business Development for Elan Drug Technologies. In addition, he was previously President and Chief Operating Officer of Circ Pharma Limited, and Chief Financial Officer of Agenus Inc. Peter also worked for the international public accounting firm of KPMG for seven years in Ireland and France and is a fellow of Chartered Accountants Ireland. He holds a Bachelor of Commerce degree from University College Cork, Ireland.
Linda S. Palczuk has been a member of the Avadel Board of Directors since July 2018. Since September 2019, Linda has been the Chief Operating Officer and a Director of Envara Health, Inc., a medical nutrition technology company. Prior to Envara Health, Linda was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, and before that, she was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Linda also had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general management roles, including Vice President, Established Brands; Vice President, Global Commercial Excellence; Vice President, Sales & Marketing; and Vice President, Sales. Linda received a BA in biology from Franklin and Marshall College and an MBA degree from the Alfred Lerner College of Business and Economics at the University of Delaware.
Dr. Eric J. Ende has been a member of the Avadel Board of Directors since December of 2018. Eric currently serves as President of Ende BioMedical Consulting Group and as a member of Matinas BioPharma’s Board of Directors. Eric’s previous roles including serving on the Board of Progenics from 2019 until 2020 when it was acquired by Lantheus Holdings, and serving on the Board of Directors of Genzyme from 2010 until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme's Board of Directors, Eric was a member of the Audit and Risk Management Committees. Prior to acting as a Board Member for Genzyme, Dr. Ende acted as a biotechnology analyst, previously serving at Merrill Lynch, Bank of America Securities, and Lehman Brothers. Eric received undergraduate degrees from Emory University, his MD from the Icahn School of Medicine at Mount Sinai, and an MBA from NYU Stern School of Business.
Dr. Mark A. McCamish has been a member of the Avadel Board of Directors since December 2019. Dr. McCamish is currently the President and Chief Executive Officer of IconOVir Bio, a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer. Prior to IconOVir, Dr. McCamish served as President, Chief Executive Officer, and member of the Board of Directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company. From July 2009 to April 2017, Mark served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research, and academics. Mark received both a BA in physical education and an MA in ergonomics from the University of California at Santa Barbara, a PhD in nutritional sciences from Pennsylvania State University and an MD from University of California at Los Angeles.